Alpha Teknova (TKNO) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 09, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Entity Registrant Name	ALPHA TEKNOVA, INC.
Entity Central Index Key	0001850902
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Document Fiscal Period Focus	Q1
Trading Symbol	TKNO
Security12b Title	Common Stock, par value $0.00001 per share
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-40538
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3368109
Entity Address, Address Line One	2451 Bert Dr.
Entity Address, City or Town	Hollister
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95023
City Area Code	831
Local Phone Number	637-1100
Entity Common Stock, Shares Outstanding		28,222,832

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 9,121	$ 11,147
Cost of sales	6,698	5,798
Gross profit	2,423	5,349
Operating expenses:
Research and development	1,395	2,013
Sales and marketing	2,343	1,597
General and administrative	7,345	7,295
Amortization of intangible assets	286	287
Total operating expenses	11,369	11,192
Loss from operations	(8,946)	(5,843)
Other income (expenses), net
Interest income (expense), net	93	(13)
Other income, net	18	0
Total other income (expenses), net	111	(13)
Loss before income taxes	(8,835)	(5,856)
Benefit from income taxes	(18)	(359)
Net loss	$ (8,817)	$ (5,497)
Earnings Per Share Basic	$ (0.31)	$ (0.20)
Earnings Per Share Diluted	$ (0.31)	$ (0.20)
Weighted Average Number of Shares Outstanding, Basic	28,181,457	28,030,971
Weighted Average Number of Shares Outstanding, Diluted	28,181,457	28,030,971

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 30,215	$ 42,236
Accounts receivable, net of allowance for doubtful accounts of $57 thousand and $23 thousand	4,777	4,261
Inventories, net	12,151	12,247
Income taxes receivable	22	22
Prepaid expenses and other current assets	2,466	2,374
Total current assets	49,631	61,140
Property, plant and equipment, net	53,733	51,577
Operating right-of-use lease assets	18,237	19,736
Intangible assets, net	17,270	17,556
Other non-current assets	2,150	2,252
Total assets	141,021	152,261
Current liabilities:
Accounts payable	1,885	2,449
Accrued liabilities	4,758	6,203
Current portion of operating lease liabilities	2,011	2,223
Total current liabilities	8,654	10,875
Deferred tax liabilities	1,204	1,223
Other accrued liabilities	169	191
Long term debt, net	22,036	21,976
Long-term operating lease liabilities	16,871	18,111
Total liabilities	48,934	52,376
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively, zero shares issued and outstanding at September 30, 2022 and December 31, 2021	0	0
Common stock, $0.00001 par value, 490,000,000 shares authorized at September 30, 2022 and December 31, 2021, 28,130,484 and 28,012,017 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	0	0
Additional paid-in capital	155,910	154,891
Accumulated deficit	(63,823)	(55,006)
Total stockholders’ equity	92,087	99,885
Total liabilities and stockholders' equity	$ 141,021	$ 152,261

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Allowance for doubtful accounts	$ 24	$ 22
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	490,000,000	490,000,000
Common stock, shares issued	28,190,192	28,179,423
Common stock, shares outstanding	28,190,192	28,179,423

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings (Accumulated Deficit) [Member]
Beginning Balance at Dec. 31, 2021	$ 143,203		$ 150,741	$ (7,538)
Beginning Balance (in shares) at Dec. 31, 2021		28,012,017
Stock-based compensation	787		787
Issuance of common stock upon exercise of stock options	55		55
Issuance of common stock upon exercise of stock options, shares		30,462
Net loss	(5,497)			(5,497)
Ending Balance at Mar. 31, 2022	138,548		151,583	(13,035)
Ending Balance (in shares) at Mar. 31, 2022		28,042,479
Beginning Balance at Dec. 31, 2022	$ 99,885		154,891	(55,006)
Beginning Balance (in shares) at Dec. 31, 2022	28,179,423	28,179,423
Stock-based compensation	$ 1,010		1,010
Issuance of common stock upon exercise of stock options	9		9
Issuance of common stock upon exercise of stock options, shares		10,769
Net loss	(8,817)			(8,817)
Ending Balance at Mar. 31, 2023	$ 92,087		$ 155,910	$ 63,823
Ending Balance (in shares) at Mar. 31, 2023	28,190,192	28,190,192

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net loss	$ (8,817)	$ (5,497)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense	2	7
Inventory reserve	(144)	(4)
Depreciation and amortization	1,130	751
Stock-based compensation	1,010	787
Deferred taxes	(19)	(360)
Amortization of debt financing costs	90	46
Non-cash lease expense	47	106
Changes in operating assets and liabilities:
Accounts receivable	(518)	(1,319)
Inventories	240	(1,028)
Prepaid expenses and other current assets	271	(547)
Other non-current assets	102	(216)
Accounts payable	(386)	237
Accrued liabilities	(670)	762
Other	(22)	(20)
Cash used in operating activities	(7,684)	(5,201)
Investing activities:
Purchase of property, plant and equipment	(4,312)	(5,917)
Cash used in investing activities	(4,312)	(5,917)
Financing activities:
Payment of offering costs	(34)	0
Proceeds from exercise of stock options	9	55
Cash provided by financing activities	(25)	55
Change in cash and cash equivalents	(12,021)	(11,063)
Cash and cash equivalents at beginning of period	42,236	87,518
Cash and cash equivalents at end of period	30,215	76,455
Supplemental cash flow disclosures:
Income taxes paid	0	0
Interest paid	110	0
Capitalized property, plant and equipment included in accounts payable and accrued liabilities	925	3,884
Deferred offering costs included in accounts payable and accrued liabilities	329	0
Debt issuance costs included in accounts payable and accrued liabilities	30	0
Recognition of operating right-of-use lease asset	(648)	20,237
Recognition of operating lease liabilities	$ (602)	$ 20,507

Nature of the Business

Nature of the Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of th e Business Alpha Teknova, Inc. (referred to herein as the Company or Teknova), produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Product offerings include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. Teknova supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions, with catalog and custom, made-to-order products. Teknova manufactures its products at its Hollister, California headquarters and stocks inventory of raw materials, components, and finished goods at that location. The Company ships products directly from its warehouse in Hollister, California.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Accounting, Presentation and Use of Estimates The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with such rules and regulations. The unaudited condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. The Company’s critical and significant accounting estimates are influenced by the Company’s assessment of the economic environment. Actual results may differ from those estimates. Certain prior period amounts have been reclassified to conform to the current year’s presentation. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the related notes thereto as of and for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2022 (the 2022 Annual Report on Form 10-K). Refer to “ Notes to Financial Statements—Note 2. Summary of Significant Accounting Policies,” within the 2022 Annual Report on Form 10-K for a full list of the Company’s significant accounting policies. The information in those notes has not changed except as a result of normal adjustments in the interim periods. Teknova has determined that it operates in one reporting unit, one operating segment, and one reportable segment, as the chief operating decision maker of the Company reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance. Going Concern These financial statements and accompanying notes have been prepared in accordance with the provisions of Accounting Standards Codification (ASC) 205-40, Presentation of Financial Statements—Going Concern , on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has incurred operating losses in the pa st and expects to incur operating losses in the near to medium-term. We have incurred net losses of $ 8.8 million and $ 5.5 million in the three months ended March 31, 2023 and 2022, respectively, and have an accumulated deficit of $ 63.8 million as of March 31, 2023. As of March 31, 2023, the Company had $ 41.0 million in working capital, which included $ 30.2 million in cash and cash equivalents. In addition to our existing cash and cash equivalents balance, another source of liquidity is our credit facility as described below in Note 10. Long-term Debt, Net, as well as our at-the-market facility, described further in this note below. Teknova believes that our existing cash and cash equivalents as of March 31, 2023, together with the credit facility and at-the-market facility, will enable the Company to fund its operating expenses and capital expenditure requirements for at least the next 12 months. Teknova's principal liquidity requirements are to fund our operations and capital expenditures. The Company may, however, require or elect to secure additional financing as Teknova continues to execute its business strategy. If the Company is required or elects to raise additional funds, Teknova may do so through equity or debt financing, which may or may not be available on favorable terms and could require the Company to agree to covenants that limit our operating flexibility. Reduction in Workforce On February 1, 2023, the Company carried out a reduction in workforce of approximately 40 positions, aimed at reducing operating expenses. The Company incurred $ 0.7 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2023, in general and administrative expenses. At-the-Market Facility On March 30, 2023, the Company entered into a sales agreement (the ATM Facility) with Cowen and Company, LLC (Cowen), under which the Company may offer and sell, from time to time, shares of its common stock having aggregate gross proceeds of up to $ 50.0 million. The issuance and sale of these shares pursuant to the ATM Facility are deemed “ at the market ” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the Securities Act), and are registered under the Securities Act. The Company will pay a commission of up to 3.0 % of gross sales proceeds of any common stock sold under the ATM Facility. The aggregate market value of shares eligible for sale under the ATM Facility will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. The prospectus supplement filed with the SEC on March 30, 2023 is only offering shares having an aggregate offering price of $ 14.5 million. The Company will be required to file another prospectus supplement in the event the Company decides to offer more than $ 14.5 million of shares in accordance with the terms of the ATM Facility, to the extent then permitted under General Instruction I.B.6 of Form S-3. Recently Adopted Accounting Pronouncements Effective January 1, 2023, the Company adopted ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326), which introduced a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses and applied to the Company’s accounts receivable. The adoption of this standard did not have a significant impact on the Company’s condensed financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3. Revenue Recognition Teknova recognizes revenue from the sale of manufactured products and services when control of promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Control is transferred when the customer has the ability to direct the use of and obtain benefits from the goods or services. The majority of the Company’s sales agreements contain performance obligations satisfied at a point in time when control is transferred to the customer. Teknova’s revenue, disaggregated by product category, was as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Lab Essentials $ 7,257 $ 6,975 Clinical Solutions 1,609 3,812 Other 255 360 Total revenue $ 9,121 $ 11,147 Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands): For the Three Months Ended March 31, 2023 2022 United States $ 8,726 $ 10,820 International 395 327 Total revenue $ 9,121 $ 11,147

Concentrations of Risk

Concentrations of Risk	3 Months Ended
	Mar. 31, 2023
Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]
Concentrations of Risk	Note 4. Concentrations of Risk Customers Customers who accounted for 10% or more of the Company’s revenues and outstanding balance of accounts receivable are presented as follows: For the Three Months Ended March 31, As of As of 2023 2022 March 31, 2023 December 31, 2022 Distributor customer A * * 14 % 15 % Distributor customer B 19 % 13 % 25 % 17 % Direct customer A * 15 % * * Direct customer B * 12 % * * * Represents less than 10%. The Company’s customers that are distributors, as opposed to direct customers, represent highly diversified customer bases. Suppliers Suppliers who accounted for 10% or more of the Company’s inventory purchases and outstanding balance of accounts payable are presented as follows: For the Three Months Ended March 31, As of As of 2023 2022 March 31, 2023 December 31, 2022 Distributor supplier A 36 % 30 % * 11 % Distributor supplier B * 10 % * * Direct supplier A 10 % 18 % * * Direct supplier B * 11 % * * * Represents less than 10%. The Company’ s suppliers that are distributors, as opposed to direct suppliers, represent highly diversified supplier bases.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Note 8. Intangible Assets, Net The following is a summary of intangible assets with definite and indefinite lives (in thousands): Balance at March 31, 2023 Balance at December 31, 2022 Gross Accumulated Net Gross Accumulated Net Definite Lived: Customer relationships $ 9,180 $ 4,829 $ 4,351 $ 9,180 $ 4,543 $ 4,637 Indefinite Lived: Tradename 12,919 — 12,919 12,919 — 12,919 Total intangible assets $ 22,099 $ 4,829 $ 17,270 $ 22,099 $ 4,543 $ 17,556 For each of the three months ended March 31, 2023 and 2022, amortization expense was approximately $ 0.3 million. As of March 31, 2022, the remaining weighted-average useful life of definite lived intangible assets was 3.8 years. The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands): Amount Remainder of 2023 $ 862 2024 1,148 2025 1,148 2026 1,148 2027 45 Estimated future amortization expense of definite-lived intangible assets $ 4,351

Inventories, Net

Inventories, Net	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventories, Net	Note 5. Inventories, Net Inventories consist of the following (in thousands): As of As of Finished goods, net $ 8,094 $ 8,368 Work in process 155 186 Raw materials, net 3,902 3,693 Total inventories, net $ 12,151 $ 12,247

Property, Plant and Equipment,

Property, Plant and Equipment, Net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Note 6. Property, Plant, and Equipment, Net Property, plant, and equipment consist of the following (in thousands): As of As of Machinery and equipment $ 19,848 $ 19,433 Office furniture and equipment 742 628 Vehicles 262 229 Leasehold improvements 12,150 12,093 33,002 32,383 Less—Accumulated depreciation ( 5,358 ) ( 4,520 ) 27,644 27,863 Construction in progress 26,089 23,714 Total property, plant, and equipment, net $ 53,733 $ 51,577 For the three months ended March 31, 2023 and 2022, depreciation expense was approximately $ 0.8 million and $ 0.5 million, respectively. Teknova capitalizes interest on funds borrowed to finance its capital expenditures. Capitalized interest is recorded as part of an asset’s cost and depreciated over the asset’s useful life. For the three months ended March 31, 2023 and 2022, capitalized interest costs were $ 0.6 million and $ 0.3 million, respectively.

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	Note 7. Leases The Company leases office space, warehouse and manufacturing space, and equipment. The Company ’ s lease agreements have remaining lease terms of one year to 15 years , and some of these leases have renewal and termination options exercisable at the Company’s election. Terms and conditions to extend or terminate such leases are recognized as part of the right-of-use assets and lease liabilities where reasonably certain to be exercised. All of the Company ’ s leases are operating leases. Operating lease expense was $ 0.8 million for each of the three months ended March 31, 2023 and 2022. Cash paid for amounts included in the measurement of the lease liabilities was $ 0.8 million and $ 0.7 for the three months ended March 31, 2023 and 2022, respectively. The weighted-average discount rate is 4.9 % and the weighted-average remaining lease term is 9.3 years as of March 31, 2023. Maturities of operating lease liabilities at March 31, 2023 were as follows (in thousands): Amount Remainder of 2023 $ 2,167 2024 2,776 2025 2,342 2026 2,413 2027 2,416 Thereafter 11,917 Total lease payments 24,031 Less: imputed interest ( 5,149 ) Present value of lease liabilities $ 18,882

Accrued Liabilities

Accrued Liabilities	3 Months Ended
	Mar. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued Liabilities	Note 9. Accrued Liabilities Accrued liabilities were comprised of the following (in thousands): As of As of Payroll-related $ 2,429 $ 2,796 Property, plant, and equipment 832 1,966 Deferred revenue 51 198 Other 1,446 1,243 Total current accrued liabilities $ 4,758 $ 6,203

Long-Term Debt, Net

Long-Term Debt, Net	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Note 10. Long-Term Debt, Net On 7May 10, 2022, the Company entered into the Amended and Restated Credit and Security Agreement (Term Loan) as borrower, with MidCap Financial Trust (MidCap), as agent and lender, and the additional lenders from time to time party thereto (the Term Loan Credit Agreement) and the Amended and Restated Credit and Security Agreement (Revolving Loan) as borrower, with MidCap as agent and lender, and the additional lenders from time to time party thereto (the Revolving Loan Credit Agreement, together with the Term Loan Credit Agreement, the Credit Agreement). The Credit Agreement provided for a $ 57.135 million credit facility (the Credit Facility) consisting of a $ 52.135 million senior secured term loan (the Term Loan) and a $ 5.0 million working capital facility (the Revolver). The Term Loan consisted of the $ 12.0 million balance made available in 2021 under the previous credit facility and an additional $ 40.135 million, staged such that $ 5.135 million was funded upon closing of the Credit Agreement, an additional $ 5.0 million was funded on October 31, 2022, $ 10.0 million was to be available in the first half of 2023, $ 10.0 million was to be available in the second half of 2023 and $ 10.0 million was to be available in the first half of 2024, with the borrowing in the second half of 2023 and in the first half of 2024 being contingent upon achieving trailing twelve months of Clinical Solutions revenue of $ 15.0 million and $ 19.0 million, respectively, and liquidity requirements (as defined in the Credit Agreement) of $ 10.0 million and $ 15.0 million, respectively. The maximum loan amount under the Revolver was $ 5.0 million, and the Company was permitted to request the lenders to increase such amount up to $ 15.0 million. Borrowings on the Revolver were limited in accordance with a borrowing base calculation. The interest on the Term Loan was based on the annual rate of one-month London Inter-Bank Offered Rate (LIBOR) plus 6.45 %, subject to a LIBOR floor of 1.00 %. If any advance under the Term Loan was prepaid at any time, the prepayment fee was based on the amount being prepaid and an applicable percentage amount, such as 3%, 2%, or 1%, based on the date the prepayment was made after the closing date of the Term Loan. Interest on the outstanding balance of the Revolver was payable monthly in arrears at an annual rate of one-month LIBOR plus 3.75 %, subject to a LIBOR floor of 1.00 %. The maturity date of the Credit Facility is May 1, 2027 . On the date of termination of the Term Loan or the date on which the obligations under the Term Loan become due and payable in full, the Company would pay an exit fee in an amount equal to 5.00 % of the total aggregate principal amount of term loans made pursuant to the Term Loan as of such date. The Credit Agreement contained a financial covenant based upon a trailing twelve months of net revenue, including a requirement of $ 42.5 million in the twelve months ending December 31, 2022. On November 8, 2022, the Company entered into Amendment No. 1 to the Credit Agreement (Amendment No. 1) which (i) replaced the LIBOR-based interest rate with a rate equal to the forward-looking one-month term Secured Overnight Financing Rate adjusted upward by 0.10 % (or Term SOFR, as defined in Amendment No. 1) plus an applicable margin ( 6.45 % for the Term Loan and 3.75 % for the Revolver), with a Term SOFR floor of 1.00 %, and with such interest rate calculation change taking effect on December 1, 2022, (ii) increased the applicable prepayment fee percentage amounts by one percentage point, (iii) gave the lenders discretion regarding the $ 10.0 million in borrowing that was previously guaranteed to be available under the Term Loan in the first half of 2023, and (iv) reduced the requirements for trailing twelve months of net revenue for all future periods. Concurrent with Amendment No. 1, the exit fee due on the date of termination of the Term Loan, or the date on which the obligations under the Term Loan become due and payable in full, increased from 5.00 % to 7.00 % of the total aggregate principal amount of term loans made pursuant to the Term Loan as of such date. On March 28, 2023, the Company entered into Amendment No. 2 to the Credit Agreement (Amendment No. 2 or as amended the Amended Credit Agreement ) which (i) increased the applicable margin from 6.45 % to 7.00 % for the Term Loan and from 3.75 % to 4.00 % for the Revolver, and increased the Term SOFR floor from 1.00 % to 4.50 % on both the Term Loan and Revolver, (ii) gave the lenders discretion regarding the $ 10.0 million in borrowings in the second half of 2023 and the $ 10.0 million in borrowings in the first half of 2024 by removing the trailing twelve month Clinical Solutions revenue requirement that was previously required under the Term Loan, (iii) removed the increase in the minimum cash covenant from $10.0 million to $15.0 million on the $10.0 million in borrowings in the first half of 2024, and added the $10.0 million minimum cash covenant requirement throughout the remaining term of the Amended Credit Agreement , and (iv) reduced the requirements for trailing twelve months of net revenue for all future periods—for example, for the twelve months ending December 31, 2023, the minimum net revenue requirement was reduced from $ 45.0 million to $ 42.0 million. Concurrent with Amendment No. 2, the exit fee due on the date of termination of the Amended Term Loan, or the date on which the obligations under the Term Loan become due and payable in full, increased from 7.00 % percent to 8.50 % of the total aggregate principal amount of term loans made pursuant to the Term Loan (including amendments thereto) as of such date. Other than the modifications described in this paragr aph and in Item 9B in the 2022 Annual Report on Form 10-K , the Amended Credit Agreement continues unmodified in all other material respects. Long-term debt, net consists of the following (in thousands): As of As of Long-term debt $ 22,135 $ 22,135 Cumulative accretion of exit fee 234 161 Unamortized debt discount and debt issuance costs ( 333 ) ( 320 ) Long-term debt, net $ 22,036 $ 21,976 At March 31, 2023, the scheduled maturities of the Company ’ s debt obligations were as follows (in thousands): Amount Remainder of 2023 $ — 2024 — 2025 6,456 2026 11,068 2027 4,611 Total $ 22,135 As of March 31, 2023, the fair value of the Company ’ s long-term debt approximated its carrying value. The fair value of the Company ’ s long-term debt was based on observable market inputs (Level 2).

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	Note 11. Stock-Based Compensation Equity Incentive Plans The Company maintains a stock incentive plan, which permits the granting of incentive stock options or nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other stock-based awards. The equity-based awards for employees will vest over a four-year period, pursuant to two different vesting schedules. For initial equity-based awards granted to employees, the first vest is generally a one-year cliff vest, followed by monthly vesting for the final three years. Thereafter, annual equity-based awards granted to employees typically vest monthly over the four-year vest term. The initial equity-based awards granted to the Company’s non-employee, independent directors upon appointment to the board of directors will vest over a three-year period, with the first vest being a one-year cliff, followed by monthly vesting over the remaining two years. Thereafter, annual equity-based awards granted to the Company’s non-employee, independent directors will cliff vest after one year from the date of grant. Stock Options The following table summarizes the stock option activity for the three months ended March 31, 2023 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2023 3,846,532 $ 7.02 8.31 $ 9,083 Granted 542,052 $ 5.41 Exercised ( 10,769 ) $ 0.84 Forfeited ( 118,161 ) $ 12.69 Expired ( 780 ) $ 15.09 Outstanding at March 31, 2023 4,258,874 $ 6.68 8.10 $ 3,783 Exercisable at March 31, 2023 1,584,270 $ 5.30 7.46 $ 2,187 Vested and expected to vest at March 31, 2023 3,974,192 $ 7.12 8.26 $ 3,070 The weighted average assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2023, were as follows: For the Three Months Ended March 31, 2023 2022 Estimated dividend yield - % - % Weighted-average expected stock price volatility 35.04 % 33.10 % Weighted-average risk-free interest rate 4.11 % 2.01 % Expected average term of options (in years) 6.25 6.25 Weighted-average fair value of common stock $ 5.41 $ 15.07 Weighted-average fair value per option $ 2.29 $ 5.48 Restricted Stock The following table summarizes the restricted stock unit activity for the three months ended March 31, 2023 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2023 28,071 $ 7.43 0.42 $ 158 Granted 118,150 $ 5.41 Vested — $ — Forfeited — $ — Outstanding at March 31, 2023 146,221 $ 5.80 1.98 $ 433 Vested and expected to vest at March 31, 2023 142,221 $ 5.80 1.98 $ 433 Employee Stock Purchase Plan The Company also maintains an employee stock purchase plan (ESPP) that authorizes the issuance of shares of common stock pursuant to purchase rights granted to eligible employees. Unless otherwise determined by the Company’s board of directors, shares of the Company’s common stock will be purchased for the accounts of employees participating in the Company’s ESPP at a price per share equal to the lesser of (i) 85 % of the fair market value of a share of the Company’s common stock on the first day of an offering; or (ii) 85 % of the fair market value of a share of the Company’s common stock on the date of purchase. Offering periods are generally six months long; beginning on May 15, 2023, offering periods begin on June 1 and December 1 of each year. The Company did no t issue any shares of common stock under the ESPP during either of the three months ended March 31, 2023 or 2022. Stock-Based Compensation Expense Stock-based compensation expense included in the accompanying condensed financial statements was as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Cost of sales $ 36 $ 19 Research and development 37 65 Sales and marketing 152 99 General and administrative 785 604 Total stock-based compensation expense $ 1,010 $ 787 Stock-based compensation expense related to stock options was $ 0.9 million and $ 0.8 million for the three months ended March 31, 2023 and 2022, respectively. Unrecognized compensation expense related to stock options was $ 9.8 million at March 31, 2023, which is expected to be recognized as expense over the weighted-average period of 3.17 years. Stock-based compensation expense related to restricted stock units was $ 0.1 million and zero for the three months ended March 31, 2023 and 2022, respectively. Unrecognized compensation expense related to restricted stock units was $ 0.7 million at March 31, 2023, which is expected to be recognized as expense over the weighted-average period of 3 .19 years. Stock-based compensation expense related to the ESPP was not significant for either of the three months ended March 31, 2023 or 2022 . Total compensation cost related to the ESPP not yet recognized also was not significant in those periods. As of March 31, 2023, an insignificant amount has been withheld on behalf of employees for future purchases under the ESPP.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes For the three months ended March 31, 2023, the Company's income tax benefit was not significant, compared to the three months ended March 31, 2022, when the Company recorded a $ 0.4 million income tax benefit. The effective tax rates for the three months ended March 31, 2023 and 2022 were 0.2 % and 6.1 %, respectively. The effective tax rates differ from the federal statutory rate primarily due to losses not expected to be benefitted.

Net Loss Per Share

Net Loss Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Per Share	Note 13. Net Loss Per Share Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents to the extent they are dilutive. For purposes of this calculation, stock options, restricted stock units, and employee stock purchase rights are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive for all periods presented. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): For the Three Months Ended March 31, 2023 2022 Net loss $ ( 8,817 ) $ ( 5,497 ) Weighted average shares used in computing net loss per share—basic and diluted 28,181,457 28,030,971 Net loss per share—basic and diluted $ ( 0.31 ) $ ( 0.20 ) Th e following is a summary of the common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive: For the Three Months Ended March 31, 2023 2022 Employee share-based awards to purchase common stock 3,833,546 2,844,368

Related Parties

Related Parties	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions Disclosure	Note 14. Related Parties The Company has identified Meeches LLC (Meeches) as a related party through common control. Meeches is controlled by Ted Davis and Irene Davis, founders and current directors, and greater than five percent stockholders of the Company. The Company leases certain real property in Mansfield, Massachusetts, from Meeches and did not have any outstanding balances owed to Meeches as of March 31, 2023 or December 31, 2022. For the three months ended March 31, 2023 and 2022, the Company paid Meeches lease payments of $ 0.1 million and $ 0.1 million, respectively. On April 11, 2023, the Company and Meeches entered into an agreement to terminate the Mansfield lease with effect no later than on June 30, 2023. The Company does not believe that the termination of the lease is or will be material to the Company.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Presentation and Use of Estimates	Basis of Accounting, Presentation and Use of Estimates The accompanying unaudited condensed interim financial statements and related notes have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and applicable rules and regulations of the Securities and Exchange Commission (SEC) regarding interim financial reporting. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with such rules and regulations. The unaudited condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the results for the interim periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain amounts of assets, liabilities, revenue, expenses, and related disclosures at the date of the financial statements and during the reporting period. The Company’s critical and significant accounting estimates are influenced by the Company’s assessment of the economic environment. Actual results may differ from those estimates. Certain prior period amounts have been reclassified to conform to the current year’s presentation. These unaudited condensed financial statements should be read in conjunction with the Company’s audited financial statements and the related notes thereto as of and for the year ended December 31, 2022, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2022 (the 2022 Annual Report on Form 10-K). Refer to “ Notes to Financial Statements—Note 2. Summary of Significant Accounting Policies,” within the 2022 Annual Report on Form 10-K for a full list of the Company’s significant accounting policies. The information in those notes has not changed except as a result of normal adjustments in the interim periods. Teknova has determined that it operates in one reporting unit, one operating segment, and one reportable segment, as the chief operating decision maker of the Company reviews financial information presented on a consolidated basis for purposes of making operating decisions, allocating resources, and evaluating financial performance.
Going Concern	Going Concern These financial statements and accompanying notes have been prepared in accordance with the provisions of Accounting Standards Codification (ASC) 205-40, Presentation of Financial Statements—Going Concern , on the basis that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has incurred operating losses in the pa st and expects to incur operating losses in the near to medium-term. We have incurred net losses of $ 8.8 million and $ 5.5 million in the three months ended March 31, 2023 and 2022, respectively, and have an accumulated deficit of $ 63.8 million as of March 31, 2023. As of March 31, 2023, the Company had $ 41.0 million in working capital, which included $ 30.2 million in cash and cash equivalents. In addition to our existing cash and cash equivalents balance, another source of liquidity is our credit facility as described below in Note 10. Long-term Debt, Net, as well as our at-the-market facility, described further in this note below. Teknova believes that our existing cash and cash equivalents as of March 31, 2023, together with the credit facility and at-the-market facility, will enable the Company to fund its operating expenses and capital expenditure requirements for at least the next 12 months. Teknova's principal liquidity requirements are to fund our operations and capital expenditures. The Company may, however, require or elect to secure additional financing as Teknova continues to execute its business strategy. If the Company is required or elects to raise additional funds, Teknova may do so through equity or debt financing, which may or may not be available on favorable terms and could require the Company to agree to covenants that limit our operating flexibility.
Reduction in Workforce	Reduction in Workforce On February 1, 2023, the Company carried out a reduction in workforce of approximately 40 positions, aimed at reducing operating expenses. The Company incurred $ 0.7 million of costs in connection with the reduction in workforce related to severance pay and other termination benefits. The costs associated with the reduction in workforce were recorded in the quarter ended March 31, 2023, in general and administrative expenses.
At-the-Market Facility	At-the-Market Facility On March 30, 2023, the Company entered into a sales agreement (the ATM Facility) with Cowen and Company, LLC (Cowen), under which the Company may offer and sell, from time to time, shares of its common stock having aggregate gross proceeds of up to $ 50.0 million. The issuance and sale of these shares pursuant to the ATM Facility are deemed “ at the market ” offerings as defined in Rule 415 under the Securities Act of 1933, as amended (the Securities Act), and are registered under the Securities Act. The Company will pay a commission of up to 3.0 % of gross sales proceeds of any common stock sold under the ATM Facility. The aggregate market value of shares eligible for sale under the ATM Facility will be subject to the limitations of General Instruction I.B.6 of Form S-3, to the extent required under such instruction. The prospectus supplement filed with the SEC on March 30, 2023 is only offering shares having an aggregate offering price of $ 14.5 million. The Company will be required to file another prospectus supplement in the event the Company decides to offer more than $ 14.5 million of shares in accordance with the terms of the ATM Facility, to the extent then permitted under General Instruction I.B.6 of Form S-3.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Effective January 1, 2023, the Company adopted ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326), which introduced a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses and applied to the Company’s accounts receivable. The adoption of this standard did not have a significant impact on the Company’s condensed financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	Teknova’s revenue, disaggregated by product category, was as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Lab Essentials $ 7,257 $ 6,975 Clinical Solutions 1,609 3,812 Other 255 360 Total revenue $ 9,121 $ 11,147 Teknova’s revenue, disaggregated by geographic region, was as follows (in thousands): For the Three Months Ended March 31, 2023 2022 United States $ 8,726 $ 10,820 International 395 327 Total revenue $ 9,121 $ 11,147

Concentrations of Risk (Tables)

Concentrations of Risk (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value, Concentration of Risk, Financial Assets, Balance Sheet Groupings [Abstract]
Summary Of Company Revenues And Outstanding Balance Of Accounts Receivable	Customers who accounted for 10% or more of the Company’s revenues and outstanding balance of accounts receivable are presented as follows: For the Three Months Ended March 31, As of As of 2023 2022 March 31, 2023 December 31, 2022 Distributor customer A * * 14 % 15 % Distributor customer B 19 % 13 % 25 % 17 % Direct customer A * 15 % * * Direct customer B * 12 % * * * Represents less than 10%.
Summary Of Company Inventory Purchases And Outstanding Balance Of Accounts Payable	Suppliers who accounted for 10% or more of the Company’s inventory purchases and outstanding balance of accounts payable are presented as follows: For the Three Months Ended March 31, As of As of 2023 2022 March 31, 2023 December 31, 2022 Distributor supplier A 36 % 30 % * 11 % Distributor supplier B * 10 % * * Direct supplier A 10 % 18 % * * Direct supplier B * 11 % * * * Represents less than 10%.

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets with Definite and Indefinite Lives	The following is a summary of intangible assets with definite and indefinite lives (in thousands): Balance at March 31, 2023 Balance at December 31, 2022 Gross Accumulated Net Gross Accumulated Net Definite Lived: Customer relationships $ 9,180 $ 4,829 $ 4,351 $ 9,180 $ 4,543 $ 4,637 Indefinite Lived: Tradename 12,919 — 12,919 12,919 — 12,919 Total intangible assets $ 22,099 $ 4,829 $ 17,270 $ 22,099 $ 4,543 $ 17,556
Schedule of Future Amortization Expense	As of March 31, 2022, the remaining weighted-average useful life of definite lived intangible assets was 3.8 years. The estimated future amortization expense of intangible assets with definite lives is as follows (in thousands): Amount Remainder of 2023 $ 862 2024 1,148 2025 1,148 2026 1,148 2027 45 Estimated future amortization expense of definite-lived intangible assets $ 4,351

Inventories, Net (Tables)

Inventories, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory, Net	Inventories consist of the following (in thousands): As of As of Finished goods, net $ 8,094 $ 8,368 Work in process 155 186 Raw materials, net 3,902 3,693 Total inventories, net $ 12,151 $ 12,247

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Components of Property, Plant and Equipment, Net	Property, plant, and equipment consist of the following (in thousands): As of As of Machinery and equipment $ 19,848 $ 19,433 Office furniture and equipment 742 628 Vehicles 262 229 Leasehold improvements 12,150 12,093 33,002 32,383 Less—Accumulated depreciation ( 5,358 ) ( 4,520 ) 27,644 27,863 Construction in progress 26,089 23,714 Total property, plant, and equipment, net $ 53,733 $ 51,577

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule Of Maturities Of Operating Lease Liabilities	Maturities of operating lease liabilities at March 31, 2023 were as follows (in thousands): Amount Remainder of 2023 $ 2,167 2024 2,776 2025 2,342 2026 2,413 2027 2,416 Thereafter 11,917 Total lease payments 24,031 Less: imputed interest ( 5,149 ) Present value of lease liabilities $ 18,882

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Accrued Liabilities, Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities were comprised of the following (in thousands): As of As of Payroll-related $ 2,429 $ 2,796 Property, plant, and equipment 832 1,966 Deferred revenue 51 198 Other 1,446 1,243 Total current accrued liabilities $ 4,758 $ 6,203

Long-Term Debt, Net (Tables)

Long-Term Debt, Net (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Summary of Components of Carrying Value of Long-Term Debt	Long-term debt, net consists of the following (in thousands): As of As of Long-term debt $ 22,135 $ 22,135 Cumulative accretion of exit fee 234 161 Unamortized debt discount and debt issuance costs ( 333 ) ( 320 ) Long-term debt, net $ 22,036 $ 21,976
Schedule of Maturities of Term Loan	At March 31, 2023, the scheduled maturities of the Company ’ s debt obligations were as follows (in thousands): Amount Remainder of 2023 $ — 2024 — 2025 6,456 2026 11,068 2027 4,611 Total $ 22,135

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Stock Options Activity	The following table summarizes the stock option activity for the three months ended March 31, 2023 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2023 3,846,532 $ 7.02 8.31 $ 9,083 Granted 542,052 $ 5.41 Exercised ( 10,769 ) $ 0.84 Forfeited ( 118,161 ) $ 12.69 Expired ( 780 ) $ 15.09 Outstanding at March 31, 2023 4,258,874 $ 6.68 8.10 $ 3,783 Exercisable at March 31, 2023 1,584,270 $ 5.30 7.46 $ 2,187 Vested and expected to vest at March 31, 2023 3,974,192 $ 7.12 8.26 $ 3,070
Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model	The weighted average assumptions used in the Black-Scholes pricing model for stock options granted during the three months ended March 31, 2023, were as follows: For the Three Months Ended March 31, 2023 2022 Estimated dividend yield - % - % Weighted-average expected stock price volatility 35.04 % 33.10 % Weighted-average risk-free interest rate 4.11 % 2.01 % Expected average term of options (in years) 6.25 6.25 Weighted-average fair value of common stock $ 5.41 $ 15.07 Weighted-average fair value per option $ 2.29 $ 5.48
Schedule of restricted stock unit activity	The following table summarizes the restricted stock unit activity for the three months ended March 31, 2023 (in thousands, except share and per share data): Number of Weighted Weighted Average Aggregate Outstanding at January 1, 2023 28,071 $ 7.43 0.42 $ 158 Granted 118,150 $ 5.41 Vested — $ — Forfeited — $ — Outstanding at March 31, 2023 146,221 $ 5.80 1.98 $ 433 Vested and expected to vest at March 31, 2023 142,221 $ 5.80 1.98 $ 433
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense included in the accompanying condensed financial statements was as follows (in thousands): For the Three Months Ended March 31, 2023 2022 Cost of sales $ 36 $ 19 Research and development 37 65 Sales and marketing 152 99 General and administrative 785 604 Total stock-based compensation expense $ 1,010 $ 787

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Computation of Basic And Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per share data): For the Three Months Ended March 31, 2023 2022 Net loss $ ( 8,817 ) $ ( 5,497 ) Weighted average shares used in computing net loss per share—basic and diluted 28,181,457 28,030,971 Net loss per share—basic and diluted $ ( 0.31 ) $ ( 0.20 )
Summary of Common Stock Equivalents Excluded from Calculation of Diluted Loss per Share	Th e following is a summary of the common stock equivalents for the securities outstanding during the respective periods that have been excluded from the computation of diluted net loss per common share, as their effect would be anti-dilutive: For the Three Months Ended March 31, 2023 2022 Employee share-based awards to purchase common stock 3,833,546 2,844,368

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details) $ in Thousands			3 Months Ended
	Mar. 30, 2023 USD ($)	Feb. 01, 2023 USD ($) Positions	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
Net loss			$ (8,817)	$ (5,497)
Accumulated deficit			(63,823)		$ (55,006)
Working captial			41,000
Cash and cash equivalents			$ 30,215	$ 76,455	$ 42,236	$ 87,518
Reduction In Work force Of Positions | Positions		40
Severance And Other Related Termination Benefits		$ 700
At-the-Market Facility [Member]
Accounting Policies [Abstract]
Maximum Value Of Stock To Be Issued Under ATM Facility	$ 50,000
Percentage Of Commission To Be Paid On Gross Sales Proceeds Of ATM Facility	3%
ATM Facility Available Value Of Stock To Be Issued Under Prospectus Supplement	$ 14,500

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation Of Revenue [Line Items]
Revenue	$ 9,121	$ 11,147
United States [Member]
Disaggregation Of Revenue [Line Items]
Revenue	8,726	10,820
International [Member]
Disaggregation Of Revenue [Line Items]
Revenue	395	327
Lab Essentials [Member]
Disaggregation Of Revenue [Line Items]
Revenue	7,257	6,975
Clinical Solutions [Member]
Disaggregation Of Revenue [Line Items]
Revenue	1,609	3,812
Other [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 255	$ 360

Concentrations of Risk - Summar

Concentrations of Risk - Summary of revenues and outstanding balance of accounts receivable (Details) - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Accounts Receivable [Member] | Distributor customer A [Member]
Product Information [Line Items]
Concentration Risk Percentage	14%		15%
Accounts Receivable [Member] | Distributor customer B [Member]
Product Information [Line Items]
Concentration Risk Percentage	25%		17%
Revenue Benchmark [Member] | Distributor customer B [Member]
Product Information [Line Items]
Concentration Risk, Percentage	19%	13%
Revenue Benchmark [Member] | Direct customer A [Member]
Product Information [Line Items]
Concentration Risk, Percentage		15%
Revenue Benchmark [Member] | Direct customer B [Member]
Product Information [Line Items]
Concentration Risk, Percentage		12%

Concentrations of Risk - Summ_2

Concentrations of Risk - Summary of inventory purchases and outstanding balance of accounts payable (Details) - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Distributor supplier A [Member] | Accounts Payable [Member]
Product Information [Line Items]
Concentration Risk Percentage			11%
Distributor supplier A [Member] | Inventory Purchases [Member]
Product Information [Line Items]
Concentration Risk, Percentage	36%	30%
Distributor supplier B [Member] | Inventory Purchases [Member]
Product Information [Line Items]
Concentration Risk, Percentage		10%
Direct supplier A [Member] | Inventory Purchases [Member]
Product Information [Line Items]
Concentration Risk, Percentage	10%	18%
Direct supplier B [Member] | Inventory Purchases [Member]
Product Information [Line Items]
Concentration Risk, Percentage		11%

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods, net	$ 8,094	$ 8,368
Work in process	155	186
Raw materials, net	3,902	3,693
Total inventories, net	$ 12,151	$ 12,247

Property, Plant and Equipment_3

Property, Plant and Equipment, Net - Summary of Components of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 33,002	$ 32,383
Less—Accumulated depreciation	(5,358)	(4,520)
Property, plant and equipment, after depreciation	27,644	27,863
Construction in progress	26,089	23,714
Total property, plant and equipment, net	53,733	51,577
Machinery and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	19,848	19,433
Office Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	742	628
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	262	229
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, plant and equipment, gross	$ 12,150	$ 12,093

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation	$ 0.8	$ 0.5
Capitalized interest costs	$ 0.6	$ 0.3

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating lease expense	$ 0.8	$ 0.8
Lease liabilities cash paid	$ 0.8	$ 0.7
Weighted-average discount rate	4.90%
Weighted-average remaining lease term	9 years 3 months 18 days
Maximum [Member]
Remaining lease terms	15 years
Minimum [Member]
Remaining lease terms	1 year

Leases - Schedule of maturities

Leases - Schedule of maturities of operating lease liabilities (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Lessee Disclosure [Abstract]
Remainder of 2023	$ 2,167
2024	2,776
2025	2,342
2026	2,413
2027	2,416
Thereafter	11,917
Total lease payments	24,031
Less: imputed interest	(5,149)
Present value of lease liabilities	$ 18,882

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Intangible Assets [Line Items]
Amortization of intangible assets	$ 286	$ 287
Acquired finite-lived intangible assets, weighted average useful life		3 years 9 months 18 days

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Intangible Assets with Definite and Indefinite Lives (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Intangible Assets [Line Items]
Intangible Assets, Gross	$ 22,099	$ 22,099
Intangible Assets, Accumulated Amortization	4,829	4,543
Intangible Assets, Net, Total	17,270	17,556
Trade Names [Member]
Intangible Assets [Line Items]
Intangible Assets, Gross	12,919	12,919
Intangible Assets, Accumulated Amortization	0	0
Intangible Assets, Net, Total	12,919	12,919
Customer Relationships [Member]
Intangible Assets [Line Items]
Intangible Assets, Gross	9,180	9,180
Intangible Assets, Accumulated Amortization	4,829	4,543
Intangible Assets, Net, Total	$ 4,351	$ 4,637

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2023	$ 862
2024	1,148
2025	1,148
2026	1,148
2027	45
Estimated future amortization expense of definite-lived intangible assets	$ 4,351

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accrued Liabilities, Current [Abstract]
Payroll-related	$ 2,429	$ 2,796
Property, plant and equipment	832	1,966
Deferred revenue	51	198
Other	1,446	1,243
Total current accrued liabilities	$ 4,758	$ 6,203

Long-Term Debt, Net - Additiona

Long-Term Debt, Net - Additional information (Details) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Mar. 28, 2023

Nov. 08, 2022

May 10, 2022

Nov. 30, 2022

Mar. 31, 2023

Jun. 30, 2024

Dec. 31, 2023

Dec. 31, 2023

Mar. 31, 2024

Jun. 30, 2023

Dec. 31, 2022

Oct. 31, 2022

Mar. 26, 2021

Debt Instrument [Line Items]

Maximum amount borrowed

$ 5,000,000

Line of credit working capital

$ 5,000,000

Maximum amount borrowed at the end of month

5,135,000

Unused Borrowing Capacity Amount

$ 40,135,000

$ 5,000,000

Cash Received Under the Term Loan

$ 12,000,000

Line of Credit Facility, Description

If any advance under the Term Loan was prepaid at any time, the prepayment fee was based on the amount being prepaid and an applicable percentage amount, such as 3%, 2%, or 1%, based on the date the prepayment was made after the closing date of the Term Loan.

Net revenue requirement for the financial covenant

$ 42,500,000

Term Loan Exit Fee Rate

5%

Long-term Debt, Gross

22,135,000

$ 22,135,000

Long term debt, net

$ 22,036,000

$ 21,976,000

Maximum [Member]

Debt Instrument [Line Items]

Term Loan Exit Fee Rate

7%

Minimum [Member]

Debt Instrument [Line Items]

Term Loan Exit Fee Rate

5%

Forecast [Member]

Debt Instrument [Line Items]

Unused Borrowing Capacity Amount

$ 10,000,000

$ 10,000,000

$ 10,000,000

$ 10,000,000

Contingent Revenue

19,000,000

15,000,000

Liquidity, line of credit

$ 15,000,000

$ 10,000,000

Amended Credit Agreement [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Description

removed the increase in the minimum cash covenant from $10.0 million to $15.0 million on the $10.0 million in borrowings in the first half of 2024, and added the $10.0 million minimum cash covenant requirement throughout the remaining term of the Amended Credit Agreement

Increase Borrowing Capacity

$ 15,000,000

Net revenue requirement for the financial covenant

$ 45,000,000

Line of credit

$ 10,000,000

Maturity date

May 01, 2027

Term loan exit fee

$ 7,000

Amended Credit Agreement [Member] | Forecast [Member]

Debt Instrument [Line Items]

Maximum amount borrowed

$ 10,000,000

$ 10,000,000

Net revenue requirement for the financial covenant

42,000,000

Term loan exit fee

$ 8,500

Amended Credit Agreement [Member] | LIBOR [Member]

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate

3.75%

Amended Credit Agreement [Member] | LIBOR Floor [Member]

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate

1%

Amended Credit Agreement [Member] | SOFR [Member]

Debt Instrument [Line Items]

Adjusted upward rate

0.10%

Term SOFR floor

1%

The Facility [Member]

Debt Instrument [Line Items]

Maximum amount borrowed

$ 57,135,000

Revolver [Member] | Amended Credit Agreement [Member]

Debt Instrument [Line Items]

Term SOFR floor

4.50%

Revolver [Member] | Amended Credit Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Exit Fees Percentage of Term Loan

4%

Revolver [Member] | Amended Credit Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Exit Fees Percentage of Term Loan

3.75%

Revolver [Member] | Amended Credit Agreement [Member] | SOFR [Member]

Debt Instrument [Line Items]

Applicable margin

3.75%

Senior Secured Term Loan [Member]

Debt Instrument [Line Items]

Maximum amount borrowed

$ 52,135,000

Term Loan [Member] | LIBOR [Member]

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate

6.45%

Term Loan [Member] | LIBOR Floor [Member]

Debt Instrument [Line Items]

Debt instrument, basis spread on variable rate

1%

Term Loan [Member] | Amended Credit Agreement [Member]

Debt Instrument [Line Items]

Term SOFR floor

1%

Term Loan [Member] | Amended Credit Agreement [Member] | Maximum [Member]

Debt Instrument [Line Items]

Applicable margin

7%

Term Loan [Member] | Amended Credit Agreement [Member] | Minimum [Member]

Debt Instrument [Line Items]

Applicable margin

6.45%

Term Loan [Member] | Amended Credit Agreement [Member] | SOFR [Member]

Debt Instrument [Line Items]

Applicable margin

6.45%

Long-Term Debt, Net - Summary o

Long-Term Debt, Net - Summary of Components of Carrying Value of Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Long term debt	$ 22,135	$ 22,135
Cumulative accretion of exit fee	234	161
Unamortized debt discount and debt issuance costs	333	320
Long-term debt, net	$ 22,036	$ 21,976

Long-Term Debt, Net - Summary_2

Long-Term Debt, Net - Summary of Scheduled Maturities of Term Loan (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Long-Term Debt, Unclassified [Abstract]
Remainder of 2023	$ 0
2024	0
2025	6,456
2026	11,068
2027	4,611
Total	$ 22,135

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to employee stock option	$ 0.9	$ 0.8
Unrecognized stock-based compensation expense	$ 9.8
Weighted-average recognition period	3 years 2 months 1 day
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense related to employee stock option	$ 0.1	$ 0
Unrecognized stock-based compensation expense	$ 0.7
Weighted-average recognition period	2 months 8 days
2021 Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Discount from market price, offering date	85%
Discount from market price, purchase date	85%
Common stock, new shares issued	0	0

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Options Activity (Details) - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Outstanding, Beginning balance	3,846,532
Number of Options, Granted	542,052
Number of Options, Exercised	(10,769)
Number of Options, Forfeited	(118,161)
Number of Options expired	(780)
Number of Options Outstanding, Ending Balance	4,258,874	3,846,532
Number of Options, Exercisable, Ending balance	1,584,270
Number of Options, Vested and expected to vest	3,974,192
Weighted Average Exercise Price per Share, Options outstanding, Beginning balance	$ 7.02
Weighted Average Exercise Price per Share, Granted	5.41
Weighted Average Exercise Price per Share, Exercised	0.84
Weighted Average Exercise Price per Share, forfeited	12.69
Weighted Average Exercise Price Per Share, Expired	15.09
Weighted Average Exercise Price per Share, Options outstanding, Ending balance	6.68	$ 7.02
Weighted Average Exercise Price per Share, Exercisable, Ending balance	5.30
Weighted Average Exercise Price per Share, Vested and expected to vest	$ 7.12
Weighted Average Remaining Contractual Term (in years), Options outstanding at January 1, 2023	8 years 1 month 6 days	8 years 3 months 21 days
Weighted Average Remaining Contractual Term (in years), Exercisable	7 years 5 months 15 days
Weighted Average Remaining Contractual Term (in years), Vested and expected to vest	8 years 3 months 3 days
Aggregate Intrinsic Value, Options outstanding	$ 3,783	$ 9,083
Aggregate Intrinsic Value, Exercisable	2,187
Aggregate Intrinsic Value, Vested and expected to vest	$ 3,070

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Weighted-Average Assumptions used in Black-Scholes Option-Pricing Model (Details) - Stock Options [Member] - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Estimated dividend yield	0%	0%
Weighted-average expected stock price volatility	35.04%	33.10%
Weighted-average risk-free interest rate	4.11%	2.01%
Expected average term of options (in years)	6 years 3 months	6 years 3 months
Weighted-average fair value of common stock	$ 5.41	$ 15.07
Weighted-average fair value per option	$ 2.29	$ 5.48

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of restricted stock unit activity (Details) - Restricted Stock Units (RSUs) [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding at January 1, 2023, Beginning balance	28,071
RSU, Granted	118,150
Outstanding at March 31, 2023, Ending balance	146,221	28,071
Vested and expected to vest at March 31, 2023	142,221
Weighted Average Grant Fair Value, Beginning Balance	$ 7.43
Weighted Average Grant Fair Value, Granted	5.41
Weighted Average Grant Fair Value, Ending Balance	5.80	$ 7.43
Weighted Average Exercise Price, Vested and expected to vest, end of period	$ 5.80
Weighted Average Remaining Contractual Term (in years), Options outstanding	1 year 11 months 23 days	5 months 1 day
Weighted Average Remaining Contractual Term, Vested and expected to vest at March 31, 2023	1 year 11 months 23 days
Aggregate Intrinsic Value, Outstanding	$ 433	$ 158
Aggregate Intrinsic Value, Vested and expected to vest at March 31, 2023	$ 433

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,010	$ 787
Cost of Sales [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	36	19
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	37	65
Selling and Marketing Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	152	99
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 785	$ 604

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Benefit from income taxes	$ (18)	$ (359)
Effective Tax Rate	0.20%	6.10%

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Computation of Basic and Diluted Net (Loss) Income Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Net loss	$ (8,817)	$ (5,497)
Weighted Average Number of Shares Outstanding, Basic	28,181,457	28,030,971
Weighted Average Number of Shares Outstanding, Diluted	28,181,457	28,030,971
Net loss per share - basic	$ (0.31)	$ (0.20)
Net loss per share - diluted	$ (0.31)	$ (0.20)

Net Loss Per Share - Summary of

Net Loss Per Share - Summary of Common Stock Equivalents Excluded from Calculation of Diluted Loss per Share Attributable to Common Stockholders (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee share-based awards to purchase common stock [Member]
Stock options to purchase common stock	3,833,546	2,844,368

Related Parties - Additional In

Related Parties - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Meeches L L C [Member]
Related Party Transaction [Line Items]
Payment for Rent Expense	$ 0.1	$ 0.1